Matt Calistri | Vice President of Corporate Strategy & Investor Relations |
Anthony Coles | Chairperson & Chief Executive Officer |
Raymond Sanchez | Chief Medical Officer |
John Renger | Chief Scientific Officer |
Mark Bodenrader | Interim Chief Financial Officer |
Michael Yee | Jefferies |
Max Skor | Morgan Stanley |
Paul Matteis | Stifel |
Jessica Fye | JPMorgan |
Umer Raffat | Evercore ISI |
Charles Duncan | Cantor |
Mohit Bansal | Wells Fargo |
Douglas Tsao | H.C. Wainwright |
Graig Suvannavejh | Mizuho Group |
Good morning ladies and gentlemen and welcome to Cerevel Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. [Operator Instructions] Please note that this call may be recorded.
I will now hand the call over to Matt Calistri, Vice President of Investor Relations.
Thank you. Good morning, everyone.